Publique un comentario 
Manifestaciones cardiovasculares asociadas a la inmunoterapia
Texto completo:
PDFResumen
La inmunoterapia comprende la utilización de los inhibidores de puntos de control en los que durante el tratamiento se ha documentado un amplio espectro de eventos adversos relacionados con el sistema inmunitario que afectan al corazón. Se realizó una revisión bibliográfica con el objetivo de describir las manifestaciones cardiovasculares asociadas a la inmunoterapia. Se utilizaron los recursos disponibles en Infomed, PubMed, a través de los motores de búsqueda Internet Explorer y Google Scholar; del total de consultas se citaron 40 referencias bibliográficas. Para la confección del informe final fueron necesario los métodos empÃricos a través de la revisión documental y métodos del nivel teórico como analÃtico y sintético.Se concluyó que las biopsias miocárdicas revelaron una amplia gama de anomalÃas, que van desde la inflamación intersticial hasta la fibrosis cardÃaca, un signo histológico de daño miocárdico. Se reportaron en pacientes que habÃan recibido inmunoterapia daños como insuficiencia cardÃaca, cardiopatÃa isquémica, cardiopatÃa coronaria, infarto agudo de miocardio, miocardiopatÃa dilatada con alta incidencia y vasculitis en pocos casos.
Palabras clave
Referencias
Pacori-Callañaupa IL,Vega-Centeno FG. Factores asociados a complicaciones cardiovasculares en pacientes con terapia oncológica del hospital nacional Adolfo Guevara Velasco del cusco, 2018[Tesis] Perú: Universidad NSAAC; 2020
McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther [Internet].2017[citado 2021 Mar 01] 31:63–75.Disponible en: https://doi.org/10.1007/s10557-016-6711-0
Jain D, Russell RR, Schwartz RG, Panjrath GS, Aronow W. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep[Internet].2017[citado 2021 Mar 01] 19:36.Disponible en: https://doi:10.1007/s11886-017-0846-x
González Morejón AE. La cardiooncologÃa pediátrica como disciplina emergente en Cuba. Rev Cubana Pediatr [Internet]. 2019[citado 2021 Abr 05] ; 91( 2):e735.Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid =S0034-75312019000200016&lng=es.
Xinqiang H, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. Npj Precision Oncology. [Internet]. 2017[citado 2021 Mar 05]31:1-11.Disponible en: https://doi.org/10.1038/s41698-017-0034-x
Abbott M, Ustoyev Y. Cancer and the immune system: The history and background of immunotherapy. Semin Oncol Nurs [Internet].2019[citado 2021 Mar 05];35:150923. Disponible en: https://www.sciencedirect.com/science/article/pii/S0749208119301056
Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med [Internet]. 2016[citado 2021 Mar 05] 4:261. Disponible en: https://doi.org/10.21037/atm.2016.04.01
Vasquez L, Castro D,León Jd, Beltrán B.Inmunoterapia en cáncer: de los inicios al premio nobel. Rev Peru Med Exp Salud Publica [Internet]. 2020[citado 2021 Mar 05];37(1):115-21. Disponible en: https://doi.org/10.17843/rpmesp.2020.371.4329
Tromp J, Steggink LC, Van Veldhuisen DJ, Gietema JA, Van der Meer P. Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther[Internet]. 2017[citado 2021 Mar 06] 101:481–90. Disponible en: https://doi.org /10.1002/cpt.614
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev[Internet]. 2016[citado 2021 Mar 06]44:51–60. Disponible en:http://refhub.elsevier.com/S0733-8651(19)30057-8/sref12
Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open[Internet]. 2019[citado 2021 Mar 06] ;2(5):e192535. Disponible en: https://doi.org/10.1001/jamanetworkopen.2019.2535
Ribas A, Wolchok JD, Cancer immunotherapy using checkpoint blockade, Science[Internet].2018[citado 2021 Mar 06] 359 (6382) 1350–1355. Disponible en: https://doi.org/10.1126/science.aar4060
Wang M et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy, FASEB J[Internet].2018[citado 2021 Mar 07] 1537–1549.Disponible en: https://doi.org/10.1096/fj.201700740R
Neilan TG, Rothenberg ML, Amiri-Kordestani L.Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist[Internet]. 2018[citado 2021 Mar 07]23:874–878. Disponible en: http://refhub.elsevier.com/S1556-0864(19)30196-0/sref3
Tocchetti CG, Galdiero MR,Varricchi G.Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-Immuno-oncology, J. Am. Coll. Cardiol[Internet].2018[citado 2021 Mar 08]71 (16) 1765–1767. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0050
Sigismund S, Avanzato D, Lanzetti L.Emerging functions of the EGFR in cancer, Mol. Oncol[Internet].2018[citado 2021 Mar 09]12 (1) 3–20. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0065
Zamorano JL et al. 2016z ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur. Heart J[Internet]. 2016[citado 2021 Mar 10]37 (36) 2768–2801. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0085
Aarti Asnani. Cardiotoxicity of Immunotherapy: Incidence,Diagnosis, and Management.Current Oncology Reports[Internet].2018[citado 2021 Mar 10] 20:44.Disponible en: https://doi.org/10.1007/s11912-018-0690-1
Florescu DR, Nistor DE. Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem. Discoveries[Internet]. 2019[citado 2021 Mar 11] 7(1); e89. Disponible en: https://doi.org/10.15190/d.2019.2
Zheng Y, Tang L, Mabardi L, Kumari S, Irvine DJ.Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or non- internalizing receptors, ACS Nano[Internet]. 2017[citado 2021 Mar 11] 11 (3)3089–3100.Disponible en: http://dx.doi.org/10.1021/acsnano.7b00078.
Heinzerling L et al.,Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy, J. Immunother Cancer[Internet].2016[citado 2021 Mar 11] 4 (1) 50. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0115
Truitt R, Mu A, Corbin EA, et al. Increased afterload augments sunitinib-induced cardiotoxicity in an engineered cardiac microtissue model. JACC Basic Transl Sci[Internet]. [citado 2021 Mar 11]20183:265–76. Disponible en: https://doi.org/10.1016/j.jacbts.2017.12.007
Salem JE et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study, Lancet Oncol [Internet]. 2018[citado 2021 Mar 12] 19 (12) 1579–1589. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0125
Chauhan A, Burkeen G, Houranieh J, Arnold S, Anthony L.Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature, Ann.Oncol[Internet].2017[citado 2021 Mar 12] 28 (8) 2034–2038. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0145
Menzies AM, Johnson DB, Ramanujam S. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol[Internet].2017[citado 2021 Mar 13] (28):368–76. Disponible en: http://dx.doi.org/10.1093/annonc/mdw443
Altan M et al. Immune Checkpoint Inhibitor–Associated Pericarditis. Journal of Thoracic Oncology[Internet].2019[citado 2021 Mar 13] 14 (6): 1102-1108. Disponible en: http://crossmark.crossref.org/dialog/?doi =10.1016/j.jtho.2019.02 .026&domain=pdf
Alessandra C et al. Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. Cardiac Failure Review[Internet]. 2019[citado 2021 Mar 13] 5(2):112–8.Disponible en: https://doi.org.10.15420/cfr.2018.32.2
Kantarjian H et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia,N. Engl. J. Med[Internet].2017[citado 2021 Mar 14] 376 (9):836–847. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0165
Zheng PP, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev[Internet].2017[citado 2021 Mar 14];00:1–49. Disponible en: https://doi.org/10.1002/med.21463
Chen J, Jiang CC, Jin L. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol[Internet]. 2016[citado 2021 Mar 15];27:409–16. Disponible en: http://dx.doi.org/10.1093/annonc/mdv615
Milling L, Zhang Y, Irvine D. Delivering safer immunotherapies for cancer. Advanced Drug Delivery Reviews[Internet].2017[citado 2021 Mar 15]1142017 79–101. Disponible en:http://dx.doi.org/10.1016/j.addr.2017.05.011
Decker WK, da Silva RF, Sanabria MH. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol[Internet]. 2017[citado 2021 Mar 15];8:829. Disponible en: http://refhub.elsevier.com/S0733-8651(19)30057-8/sref2
Dent S, Melloni C, Ivars J, Sammons S, Kimmick G. Cardiotoxicities of Modern Treatments in Breast Cancer. Curr Treat Options Cardio Med[Internet]. 2019[citado 2021 Mar 16] 21: 34.Disponible http://crossmark.crossref.org/dialog/?doi=10.1007/s11936-019-0738-z&domain=pdf
Florescu DR, Nistor DE. Therapy-induced cardiotoxicity in breast cancer patients:a well-known yet unresolved problem. Discoveries[Internet]2019[citado 2021 Mar 13] 7(1); e89. Disponible:https://doi.org/10.15190/d.2019.2
Quagliariello V. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab International Journal of Cardiology[Internet].2019 [citado 2021 Mar 13] 292171–179 Disponible en: https://doi.org/10.1016/j.ijcard.2019.05.028
Ashley F. Stein-Merlob MV. Rothberg EH. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports[Internet].2021[citado 2021 Mar 13] 23: 11 Disponible en: https://doi.org/10.1007/s11886-021-01440-3
Sanchez K, Page DB, Urba W. Immunotherapy Toxicities Surg Oncol Clin N Am [Internet].2019 [citado 2021 Mar 14] 28387–401.Disponible en: https://doi.org/10.1016/j.soc.2019.02.009
Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Pract Res Clin Haematol[Internet].2018[citado 2021 Mar 14];31(2):158–65. Disponible en: https://doi.org/10.1016/j.beha.2018.03.004.
Burstein DS, Maude SL, Grupp SA, Griffis H, Rossano JW, Lin KY. Cardiac effects of chimeric antigen receptor (CAR) T-cell therapy in children, Journal of Clinical Oncology 35 (15_suppl) [Internet].2017[citado 2021 Mar 15] 10531. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0395
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ.Toxicity and management in CAR T-cell therapy, Mol. Therapy Oncolytics[Internet]. 2016[citado 2021 Mar 15] 316011. Disponible en: http://refhub.elsevier.com/S0167-5273(20)33560-9/rf0315
Enlaces refback
- No hay ningún enlace refback.
Copyright (c) 2021 EsTuSalud
Esta obra está bajo una licencia de Creative Commons Reconocimiento 4.0 Internacional.
